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Abstract
Background: Cancer is clonal proliferation that arises owing to mutations in a subset of genes that confer growth
advantage. More and more cancer related genes are found to have accumulated somatic mutations. However, little
has been reported about mutational patterns of insertions/deletions (indels) in these genes.
Results: We analyzed indels’ abundance and distribution, the relative ratio between indels and somatic base
substitutions and the association between those two forms of mutations in a large number of somatic mutations
in the Catalogue of Somatic Mutations in Cancer database. We found a strong correlation between indels and base
substitutions in cancer-related genes and showed that they tend to concentrate at the same locus in the coding
sequences within the same samples. More importantly, a much higher proportion of indels were observed in
somatic mutations, as compared to meiotic ones. Furthermore, our analysis demonstrated a great diversity of indels
at some loci of cancer-related genes. Particularly in the genes with abundant mutations, the proportion of 3n
indels in oncogenes is 7.9 times higher than that in tumor suppressor genes.
Conclusions: There are three distinct patterns of indel distribution in somatic mutations: high proportion, great
abundance and non-random distribution. Because of the great influence of indels on gene function (e.g., the effect
of frameshift mutation), these patterns indicate that indels are frequently under positive selection and can often be
the ‘driver mutations’ in oncogenesis. Such driver forces can better explain why much less frameshift mutations are
in oncogenes while much more in tumor suppressor genes, because of their different function in oncogenesis.
These findings contribute to our understanding of mutational patterns and the relationship between indels and
cancer.
Background
Humans are increasingly exposed to food-, water- and
air-borne carcinogens, as well as specific carcinogenic
agents related to their occupational settings and life-
style choices [1,2]. Indeed, cancer is responsible for
more than one-fifth of all deaths worldwide [3] and can
be characterized by such hallmarks as uncontrollable
growth, immortality and metastasis, and induction of
inflammatory microenvironment [4]. Accumulation of
genetic changes can give rise to tumorigenesis in three
types of genes: oncogenes, tumor-suppressor genes and
stability genes [5,6]. Cancer-related genes are those
which are mutated and are causally implicated in cancer
development [7]. Unlike certain other diseases which
can be caused by mutations in one specific gene, human
cells have many safeguards to protect itself against the
lethal effects of cancer causing genetic mutations [5].
Therefore, it is the defectiveness of a subset of genes
that give rise to the development of cancer [8], and
many DNA changes in cancer genes can contribute to
the final state of tumorigenesis. Moreover, the accumu-
lation of somatic mutations in oncogenes and tumor
suppressor genes is thoughtt op l a yac r i t i c a lr o l ei n
cancer development and leads to the multi-step conver-
sion of normal cells to a malignant state [9-11].
All cancers arise from the DNA sequence changes of
the cellular genomes. However, not all changes directly
lead to the development of cancer; instead, cancer is
caused by a series of genetic alterations accumulated in
the key tumor-suppressor genes and oncogenes [6,12].
A large number of cancer genes have been identified
through decades of studies, and the pace will be raised
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nologies. The Catalog of Somatic Mutations in Cancer
(COSMIC database), a large-scale database founded by
the Wellcome Trust Sanger Institute, is designed mainly
to store and catalog somatic mutation information with
regard to human cancers. A vast amount of published
somatic mutations involved in cancer genes has been
gathered in the COSMIC database [13]. The mutated
genes are always oncogenes and tumor suppressors that
are involved in the generic processes of cell-cycle
control, signal transduction, and stress responses [8].
COSMIC was initiated in 2004 and presently is the
most comprehensive resource for information on
somatic mutations in human cancers, providing over
50,000 mutations in almost 4800 cancer genes for inves-
tigation [13,14]. The data can also be queried by sample,
which allows us to analyze different mutations occurring
within the same genome.
The most commonly observed somatic mutation in
cancer-related genes includes base substitution and
insertion/deletion (indel) [7,15]. In COSMIC, most of
the mutations are in these two forms. Previous reports
observed a co-variation of base substitutions and indels
[16-20] as well as their non-random distribution which
generate mutation hotspots in certain human disease
loci [21-23]. Recently, the nucleotide substitution rate
was found to be significantly elevated surrounding indels
and correlated with both indel size and abundance [24],
suggesting an important role played by indels as well in
the mutations of cancer-related genes. To test this
hypothesis, we investigated the distribution and abun-
dance of both indels and somatic base substitutions. We
found that the indel-centered distribution of base substi-
tution is a general pattern and that indels are particu-
larly abundant in somatic mutations of cancer-related
genes. Our finding may shed light on the mechanisms
of how cancer-related mutations arise and provide
further evidence for future directions of study on such
mechanisms.
Methods
Data source of mutations and sequences
All somatic mutational data were retrieved from COS-
MIC (v47 release; http://www.sanger.ac.uk/genetics/
CGP/cosmic/). The genomic sequence and annotation
information from the human-Ref and chimpanzee gen-
omes were obtained from the Ensembl 52 database
http://www.ensembl.org. The human-Celera and
human-Korean sequences were retrieved from the ftp
site at the NCBI ftp://ftp.ncbi.nlm.nih.gov/genomes/
H_sapiens/ and the publication by Kim et al. 2009,
respectively [25]. The homologous relationships of the
cancer genes in different genomes were confirmed by
protein similarities obtained from BLASTp searches,
except for human-Korean, whose homologous relation-
ship was already provided based on human-Ref. Peptide
sequences of the cancer genes were retrieved from the
COSMIC FTP site ftp://ftp.sanger.ac.uk/pub/CGP/
cosmic/fasta_files/.
Analysis of indels and base substitutions in the coding
regions of cancer genes
A gene in the COSMIC database is represented by a
single transcript for a given gene, and the cDNA in
COSMIC refers to the coding sequence (CDS) [13].
Only the unambiguous mutation data with definite
position and base changes in COSMIC were included
in our analysis. Twenty-five cancer genes with ≥100
mutations (either indels or somatic base substitutions)
in their CDSs were used to analyze the co-localization
of indels and base substitutions. Each CDS was equally
divided into 10 blocks, and the densities of indels and
base substitutions were calculated in each block. We
considered a cancer gene as an apparent mutation bias
("apparent” category in Table 1) if it reaches the three
criteria: a) the top three blocks with the most indels
contain 60% of all indels; b) the top three blocks with
the most substitutions contain 60% of all substitutions;
c) at least one block is shared by both indel and sub-
stitutions. To further explore the co-localization of
indels and base substitutions, the indel number in each
block was plotted against their corresponding substitu-
tion number. The co-localization was considered sig-
nificant ("significant” category in Table 1) when R
2 >
0.40 and P < 0.05 by Pearson’s correlation. Finally,
genes that do not reach the significance criteria were
deemed as insignificant.
Analysis of the distance between indel and base
substitution within the same samples
In the COSMIC database, any given sample may have
more than one mutation, which means a series of muta-
tions may occur within the same sample. Using a Perl
program, we obtained 511 samples with at least one
indel and one base substitution, and analyzed the distri-
bution of the distances between indel and its nearest
base substitution. To obtain a general view of this distri-
bution, we analyzed the data at the 20 bp and 1 bp scale
within 300 bp and 20 bp regions, respectively.
Evolutionary analysis of the genomic region of cancer
genes
The peptide sequences of cancer genes were used as a
query in BLASTp searches against proteins of other gen-
omes. The threshold of expectation value (E-value) was
set to 10
-4. The protein hits with the smallest E-value
were selected, and their corresponding genomic gene
regions were retrieved by a Perl program. The Mauve
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align the genomic sequence, and a Perl program was
used to obtain alignments that are >1000 bp. For each
indel that is <100 bp in length, the 5’ and 3’ flanking
sequences were divided into five 100 bp windows, when
both 5’ and 3’ flanking sequences are longer than 500
bp. We also validated the homologies by eliminating the
alignments with any blocks that have >10 mutations.
Results
Relative abundance of indels and base substitutions in
cancer genes
The COSMIC database contains non-redundant somatic
mutations, including samples which have been found to
be negative for mutations during screening in different
genes of different cancer types [26]. Therefore, this data
enables a comprehensive mutational frequency analysis.
In this database, one of the most significant character-
istics of cancer-related mutations is the high frequency
of indels, as compared to that of somatic base substitu-
tions. In general, indels constitute about 27% of all non-
redundant mutations in COSMIC database. The propor-
tion is even higher in the 25 genes each with ≥100
mutations that we chose to study in depth (Table 1 and
Additional file 1: Supplemental Fig. S1); among these
genes, the indels take up about half of all mutations.
Notably, the proportion of indels varies drastically
among different cancer genes. In the PIK3CA gene, for
example, base substitution is about 14 times more than
indels (Table 1). By contrast, more than 7/8 of the
mutations in the CEBPA gene are indels (Table 1). The
indels in CEBPA also display diverse types and multiple
lengths, particularly in the 3’ ends of the CDS (Fig. 1a
&1b). The indel sizes at the hot-spot (e.g., the 800 -
1078 bp region) are far from random. In this region, the
indel size ranges from 1 to 181 bp in the total of 114
indels. More surprisingly, 85% (97 out of the 114) indels
are 3n size multiples, and there are only 9 indels <3bp.
This distribution is significantly different from that of
the 1 - 800 bp of the CDS in CEBPA (Fig. 1b; Chi-
square test for 1 - 15 bp data, P <0 . 0 1 )a n da l s ot h e
overall indel sizes of all cancer genes (Additional file 1:
Table 1 Statistics of cancer genes with not less than 100 mutations
Gene
name
Total mutation
number
Number of base
substitutions
a
Number of
indels
S/I
ratio
Category of S-I
linkage
Gene type
APC 808 266 (11, 255) 542 0.49 Apparent Tumor suppressor gene
PTEN 769 407 (19, 388) 362 1.12 Insignificant Tumor suppressor gene
VHL 756 296 (38, 258) 460 0.64 Significant Tumor suppressor gene
CDKN2A 457 302 (57, 245) 155 1.95 Insignificant Tumor suppressor gene
NF2 385 80 (5, 75) 305 0.26 Significant Tumor suppressor gene
CEBPA 358 43 (8, 35) 315 0.14 Insignificant Other
KIT 312 148 (25, 123) 164 0.90 Apparent Oncogene
TP53 300 232 (5, 227) 68 3.41 Significant Tumor suppressor gene
EGFR 269 208 (19, 189) 61 3.41 Apparent Oncogene
CTNNB1 229 143 (17, 126) 86 1.66 Apparent Oncogene
NOTCH1 222 98 (9, 89) 124 0.79 Apparent Tumor suppressor gene
PIK3CA 204 190 (9, 181) 14 13.57 Apparent Oncogene
PTCH1 189 125 (10, 115) 64 1.95 Insignificant Tumor suppressor gene
NF1 182 83 (5, 78) 99 0.84 Insignificant Tumor suppressor gene
RB1 174 87 (4, 83) 87 1.00 Significant Tumor suppressor gene
ATM 162 124 (2, 122) 38 3.26 Insignificant Other
WT1 156 44 (0, 44) 112 0.39 Apparent Tumor suppressor gene
SMAD4 147 108 (4, 104) 39 2.77 Insignificant Tumor suppressor gene
RUNX1 135 60 (6, 54) 75 0.80 Apparent Tumor suppressor gene
CDH1 133 70 (6, 64) 63 1.11 Insignificant Tumor suppressor gene
FLT3 124 35 (4, 31) 89 0.39 Apparent Oncogene
MEN1 122 45 (1, 44) 77 0.58 Insignificant Tumor suppressor gene
BRAF 118 109 (16, 93) 9 12.11 Apparent Oncogene
STK11 111 66 (8, 58) 45 1.47 Significant Tumor suppressor gene
GATA1 106 20 (2, 18) 86 0.23 Apparent Other
Mean 277 136 (12, 124) 142 0.96 - -
S/I is the ratio of base substitution number and indel number. S-I represents the linkage between substitutions and indels. In column a, the two numbers in
parentheses are synonymous and non-synonymous somatic base substitutions, respectively. Gene type is “Oncogene” or “Tumor suppressor gene” whenever
there is strong evidence according to previous publications (otherwise “Other” is assigned).
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the indels.
The ratio of nucleotide substitutions to indels (S/I)
between human genome sequences is 11.39 within cod-
ing regions [27]. This ratio should reflect the abundance
of substitutions and indels in meiotic mutations. How-
ever, the COSMIC database contains mostly missense
changes [28], suggesting that the calculated substitution/
indel ratios (S/I in Table 1) might reflect their relative
importance in causing the cancer cell phenotypes.
Indeed, in COSMIC, the average ratio is far less than
11.39, indicating an important role played in by indels.
Interestingly, the indels are more abundant in the genes
with rich somatic mutations. For example, the overall S/
I ratio is 2.66 for all the 4408 genes with at least one
mutation (indel or base substitution); 1.17 for all the
251 genes with at least one indel and one base substitu-
tion; and 0.96 for all the 25 genes with ≥100 mutations.
Only in two out of the 25 genes (Table 1), the S/I ratio
is larger than 11.39. A similar trend is also observed for
non-synonymous substitutions, which are 10 times more
abundant than synonymous substitutions in the genes
with ≥100 mutations (Table 1), as compared to a ratio
of 4.5 in the overall COSMIC data.
For tumor suppressor genes, loss of function is asso-
ciated with oncogenesis, in contrast to the gain-of-func-
tion activation of oncogenes [29]. In this scenario, one
might expect that the non-3n indels, to frequently pro-
duce frameshifts, might be more frequent than the other
genes (e.g., oncogenes). In Table 1, 16 tumor suppressor
genes and six oncogenes are identified, which contain
88% and 5% of non-3n indels, respectively. The propor-
tion of non-3n indels is significantly different between
these two gene types (Fig. 1c; Chi-square test for 1 - 30
bp data, P < 0.01). The tumor suppressor genes indeed
produce more frameshift mutations than oncogenes.
Co-localization of indels and base substitutions in cancer
gene CDS
In order to uncover the mutational patterns of indels and
base substitutions in human cancer genes from COSMIC,
25 cancer genes with ≥100 mutations, either in the form
of indel or base substitution, were analyzed. They were
then classified into three categories (’apparent’, ‘signifi-
cant’ and ‘insignificant’ in Table 1) according to the
extent of co-localization between indel and base substitu-
tion (detailed criterion is described in Methods). To illus-
trate the distribution of indels and base substitutions, the
mutation data was visualized using a Perl program (com-
parison of the three categories is shown in Fig 2).
The co-localization of indel and base substitution is
visually ‘apparent’ when the first category of genes is
shown graphically (e.g., EGFR in Fig. 2a), where the indels
and substitutions are highly biased towards a certain posi-
tion in a CDS. In total, 11 ‘apparent’ genes are identified
and their mutational distributions are shown in Additional
file 1: Supplemental Fig. S3. For the other 14 genes, how-
ever, the correlation might not be graphically observed,
due to the fact that so many mutations occurred along the
CDS (for example, the genes TP53 and NF1 in Fig. 2b
&2c). When the indels and base substitutions were calcu-
lated separately in the equally divided 10 blocks of CDSs,
some genes showed close correlations between these two
types of mutations (Fig. 3 and Additional file 1: Supple-
mental Fig. S4). Five genes are classified into the second
category with a ‘significant’ correlation, based on a R
2 >
0.40 and P < 0.05. Notably, for the genes in the ‘apparent’
category, eight out of the 11 genes are also qualified well
under the ‘significant’ criteria (Additional file 1: Supple-
mental Fig. S4). However, we did not put them in the ‘sig-
nificant’ category because their mutations are sometimes
so biased that in certain blocks there is no mutation data
(e.g., CTNNB1 in Additional file 1: Supplemental Fig. S4),
making it difficult to evaluate the validity of significance.
The remaining nine genes have no significant associa-
tions between indels and substitutions and are therefore
classified into the ‘insignificant’ group (for example, NF1
in Additional file 1: Supplemental Fig. S5; Additional file
1: Supplemental Fig. S4). However, when shown in a
detailed illustration, 4 out of the 9 genes (CDKN2A,
CEBPA, SMAD4 and MEN1) have their R-square above
or close to 0.30 (Additional file 1: Supplemental Fig. S4),
indicating a minor co-localization of indel and base sub-
stitution. Furthermore, some of them displayed a clear
linkage between these two types of mutations (i.e.,
CEBPA in Fig. 1a). Therefore, we conclude that for at
least 16 out of the 25 genes (11 ‘apparent’ and 5 ‘signifi-
cant’), indels and substitutions indeed tend to co-localize
in the CDS or at least correlate strongly with each other.
Additionally, to confirm its validity of our ‘three-cate-
gory’ approach, we also explored all the 10 cancer genes
with 50 - 99 mutations, in which a highly consistent
result was obtained (Additional file 1: Supplemental Fig.
S6). Although the approach is not designed to work per-
fectly for genes with few mutations, we still found six
out of the ten genes reach the ‘apparent’ criteria, and
three (KRAS, NPM1, JAK2) of those genes reached the
significant criteria. This indicates that the pattern
observed in the genes with ≥100 mutations is common
among cancer-related genes.
Associations of indels and base substitutions within the
same sample
The results above indicate that in cancer-related genes
indels and base substitution tend to accumulate in the
same region within the CDS. This finding was based on
the analysis of the non-redundant mutational data in
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Page 4 of 11Figure 1 Abundance and size distribution of indels in the gene CEBPA and in oncogenes/tumor suppressor genes. (a) Mutational
pattern in the CDS of CEBPA; (b) comparison of indel size distribution between 1 - 800 bp and 800 - 1078 bp region in CEBPA; (c) comparison
of indel size distribution between oncogenes and tumor suppressor genes identified in Table 1. To make indels as less overlap as possible, only
≤30 bp indels are shown in (a). Only ≤30 bp indels are shown in (b) and (c).
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another perspective, we also analyzed samples each with
both indels and base substitutions in order to explore their
co-occurrence in a more direct manner. In the COSMIC
database, it is possible to analyze multiple mutations that
occurred in the same cancerous sample, and it was our
goal to study in these cases the distribution of distance
between indels and its nearest base substitutions. Samples
with at least one indel and one base substitution were ana-
lyzed. Data from 511 samples with regard to 48 cancer
genes were collected. The distance distribution between
indel and substitution is shown in Fig. 4a, and the number
of occurrences is concentrated in the 1-20 bp range, indi-
cating that indels and base substitutions indeed tend to
occur closely to each other. A detailed illustration of the
distance distribution between 1 bp and 20 bp is shown in
Fig. 4b, and the correlation is significant (R-square = 0.83
and P < 0.01) when fitted by an exponential decay curve.
In both large and small scale analyses (Fig. 4), the number
of occurrences with short distances between the indel and
substitution were higher than those with longer distances
between them. This indicates that not only do indels and
Figure 2 Examples of the genes in ‘apparent’, ‘significant’, and ‘insignificant’ categories. (a) Mutational pattern in EGFR as an example of
the ‘apparent’ category (for detailed definition, see Methods); (b) in TP53 as an example of the ‘significant’ category; (c) in NF1 as an example of
the ‘in significant’ category. Gene names are shown in green boxes. The Arrow below the gene name denotes position in the CDS, and ‘k’
means 1000 bp length of DNA. To make indels as less overlap as possible, only ≤30 bp indels are shown.
Figure 3 Illustration of significant correlation between indel and base substitution in ten-block analysis. (a) Number of mutations in ten
sequential blocks of TP53; (b) scatter plot of indels and base substitutions in TP53; Graphic view of mutations in TP53 is in Fig. 2b.
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region (as described in the previous section), but tend to
co-occur in the same sample as well.
Evolutionary view of the cancer gene regions in the three
human genomes
Our studies above revealed a close relationship between
indels and base substitutions in the CDS of human can-
cer genes. All of the results above are based on human
somatic mutations, or non-evolutionary mutations,
which have a tendency to be eliminated in the course of
evolution by natural selection. With the advent of new
sequencing technologies, more and more human gen-
omes are being sequenced. Here, we used three fully-
sequenced human genomes – human-Ref, human-Cel-
era, and human-Korean (see Methods), with chimpanzee
sequences as a reference. By analyzing the single nucleo-
tide polymorphism (SNP) distribution pattern near
indels, we found that the SNPs tend to accumulate near
the indel in the cancer related genes as well, especially
for SNPs linked with the corresponding indel (Fig. 5).
There is a slight difference between the pattern in Fig.
5a &5b, presumably due to the fact that only <30 bp
indels could be detected under the sequencing method
used to obtain the human-Korean genome, resulting in
a the relatively smaller dataset than that of human-Cel-
era. All these results were consistent with of our pre-
vious publications [24], indicating that indels have a
strong influence on a substantial amount of base substi-
tutions in their flanking regions.
Discussion
Patterns of somatic mutations
Mutations, which can be categorized into somatic and
meiotic ones, play a key role in disease progression and
in shaping genomic evolution [30,31]. One of the most
distinctive characteristic of somatic cancer mutations is
that they are not passed on to the next generation,
which renders them unaffected by natural selection.
This particular characteristic leads to a distinct pattern
between somatic and gametic mutations.
Cancers arise from somatic mutations that confer
selective growth advantages on the cells [15]. To under-
stand tumorigenesis, it is essential to define the patterns
of somatic mutation, relative frequency of indel and
base substitution, and distribution of those mutations.
The understanding of the real rate of somatic mutation
in normal human cells is still relatively rudimentary
[15]. However, mutation rate is likely to differ greatly
among different types of cancer cells or genes. For
example, in a screen of somatic mutations from 210
cancers, a great difference was found among these can-
cers [7]. Seventy-three showed no somatic mutations at
all, whereas 77 mutations per Mb were present in two
gliomas.
The relative low ratio of base substitution to indel in
the COSMIC database is interesting. This could repre-
sent a true significance of indel mutations in cancer
genes or reflect an under-representation of synonymous
substitutions in the COSMIC database because the data-
base is designed to catalog mostly missense changes
[28]. The underestimated synonymous substitutions
could be estimated when a reference database is used. A
systematic survey [7] revealed 219 synonymous and 674
non-synonymous substitutions in cancer-related genes,
equaling a ratio of 1:3.078 (or 0.3249) of Syn:Non-syn
substitutions. In the COSMIC database, we identified
2133 synonymous and 9462 non-synonymous substitu-
tions, or 1:4.436 in Syn:Non-syn substitutions. Based the
ratio 0.3249, the total synonymous substitution number
should be 3074 (= 9462 × 0.3249) and the total substitu-
tions should be 12536. After this correction, the S/I
Figure 4 Distribution of the distances between indel and the nearest base substitution in the same sample. (a) Distribution of the
distances in 20 bp scale analysis and only the distances within 300 bp are shown; (b) Distribution of the distances in one bp scale analysis and
only the distances within 20 bp are shown.
Yang et al. BMC Medical Genetics 2010, 11:128
http://www.biomedcentral.com/1471-2350/11/128
Page 7 of 11ratio should be 2.59 (= 12536/2884). Thus, a much
lower S/I ratio is still present, compared with the S/I of
11.39 in normal CDS of humans, suggesting a particular
importance of indel mutations in driving the occurrence
of cancers.
Alternatively, a low S/I ratio could also be caused by
the method of mutation screening process. Indeed,
some methods, i.e., the protein truncation test, cannot
detect mutations that cause missense amino acid substi-
tutions. However, most of the methods identify base
substitutions and small insertions/deletions [28], indicat-
ing that large indels are often underestimated. Further-
more, the sensitivity of most methods to detect
insertions and deletions is low, suggesting the need for
additional approaches to their discovery [32]. Be that as
it may, it is most likely that indel mutations are very
important in cancer genes, and many indels observed
might change the functions of oncogenes [8].
In cancer genes, large scales of somatic mutations,
either in the form of base substitutions or indels, are
highly concentrated towards certain loci in CDS (Table
1, Additional file 1: Supplemental Fig. S3 & S4, and Fig
4). Our previous studies suggested the presence of indels
as local mutation enhancers in surrounding sequences
in a variety of organisms [24,33] and indicated the non-
trivial role indels play in controlling differences of
genetic variation and divergence across functional
regions of a genome [27]. Compared to meiotic muta-
tions accumulated in the course of evolution, the
somatic mutations in cancer genes obviously boasts a
much higher correlation of indels and base substitutions
in cancer genes. The close correlation between indels
and base substitutions at specific regions indicates that
those two forms of somatic mutations are essentially
associated with the promotion of oncogenesis.
The co-localization of indels and base substitutions
in somatic mutations of cancer genes raises an
interesting question: how did it occur. The hypothesis
that indels induce local mutation during meiosis [24]
probably does not apply to somatic tissues because
homologous chromosomes do not pair during mitosis.
Although there had been reports of pairing of certain
chromosomal regions in mammalian cells, the
observed frequency was low [34,35]. This co-localiza-
tion could result from the mutability of specific
sequence influenced by its compositional property or
its intensity from natural selection. In this case, both
types of mutations like to occur simultaneously in
response to a region’s functional constraint. The
uneven distribution of somatic mutations had been
observed across the genome in cancer genes [32], how-
ever, the data alone cannot validate this hypothesis.
Alternatively, this co-localization could be particularly
associated with the development of cancer cells, which
eventually causes genome instability or their growth
advantage. In this scenario, both base substitutions and
indels could occur abruptly in large number after a
certain stage of cancer cell development. The lower S/I
ratio (0.95) in the genes with more somatic mutations
(Table 1) indicates that a large number of indels
occurred preferentially at the stage when somatic
mutation overflows. This hypothesis could be tested by
exhaustive detection of both mutation types in the
process of cancer cell development in future. The
sequencing technologies for such detection are still
under development. The generation of thousands of
comprehensive and high quality somatic mutations will
provide powerful insights into the exact mechanism of
co-localization of somatic base substitutions and
indels.
Potential effects of indel mutations on cancer genes
Indel mutations theoretically should be more deleterious
than base substitutions, including nonsynonymous
Figure 5 Evolutionary analysis of SNP distribution in indel flanking regions in cancer genes. (a) SNP distribution pattern from the
alignments of human-Celera, human-Ref, and chimpanzee sequences. (b) SNP distribution pattern from the alignments of human-Korean,
human-Ref, and chimpanzee sequences. ‘O’ denotes indel’s position. L1-L5 represents the five bins (100 bp each) in the 5’ flanking region, and
R1-R5 represents the five bins (100 bp each) in the 3’ flanking region. ‘Indel haplotype’ denotes the SNPs shared with indel haplotype, and ‘non-
indel haplotype’ denotes the SNPs which are not shared with indel haplotype.
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tion of selective effects, ranging from completely neutral
to lethal. Indel mutations, on the other hand, will defi-
nitely cause amino acid changes when indel sizes are 3n
or trigger frameshift mutations when they are non-3n.
Thus, as selective constraint on protein function
increases, selective effects of indels and non-synon-
ymous mutations in the same codons or functional
regions of a protein are correlated but with indels
increasing in their negative selective effects faster than
amino acid replacement changes.
It is well-known that there are two kinds of muta-
tions, the ‘driver’ and ‘passenger’ mutations [15]. Dri-
ver mutations can confer a selective growth advantage
and has been positively selected in oncogenesis [7],
while the passenger mutations likely have no contribu-
tion to the genesis of cancers [15]. A higher ratio of
non-synonymous:synonymous somatic mutations than
expected by random indicates the presence of positive
selection and driver mutations [7]. A genome-wide
survey revealed an excess of non-synonymous muta-
tions compared with that expected and thus provided
evidence for the existence of driver mutations [7].
Similarly, a higher proportion of 3n indels compared
with what is expected by chance (1/3 for example) sug-
gests a positive selection for such size indels. In fact,
the expected value should be less than 1/3 because 1-2
bp indels are dominant in cancer genes. As shown in
Additional file 1: Supplemental Table S1, 49% of indels
of COSMIC database are 1-2 bp ones and 23% are 3n
ones. In the 16 tumor suppressor genes with ≥100
mutations, 58% of indels are 1-2 bp ones and 12% of
indels are 3n ones. In contrast, the ratio is 3% and
95% respectively for the six oncogenes with ≥100
mutations, where the proportion of 3n indels is 7.9
times larger than that of the tumor suppressor genes
(The result is quite similar when using genes with ≥50
mutations). This strongly indicates that 3n indels at
some of cancer-related genes are under positive selec-
tion and could often be the ‘driver mutation’.T h e r e -
fore it is reasonable to assume that specific driving
forces may exist for 3n indels, which could change the
function of a gene but not abolish it by frameshift
mutation in cancer genes. The particular abundance of
indels in the COSMIC database also indicates that
indels themselves are positively selected in somatic
mutations of cancer genes. In this scenario, more
focused studies on indel mutations are especially
important for understanding of somatic mutations on
oncogenesis.
Studies of various organisms have shown that the
occurrence of mutations (particularly indels) is highly
influenced by the context and position in the genome
[27,31]. In functional sequences, such as coding regions,
indels are subject to purifying selection to remove their
deleterious effects on gene functions. Different from
meiotic mutations, indels have much less selective pres-
sure in somatic mutations, particularly in cancer genes.
Given that indels are more likely to be drivers, a sub-
stantial number of indels in the CDS of cancer genes
are not surprising. For example, 12 genes out of 25
s h o w ni nT a b l e1h a v em o r ei n d e l st h a nS N P si nC D S ,
and such a great proportion of indels in CDS is rarely
seen in meiotic mutations. The abundance of indels,
which have a comparatively greater influence than
SNPs, is consistent with the abnormal function and
devastating characteristics of cancer.
Indel hot-spots in somatic mutations of cancer genes
The mutation pattern of cancer genes demonstrated a
distinctive pattern of the indel hot-spots. As shown in
Fig. 1a, the indels are not randomly distributed across a
gene. They tend to occur at a specific region, e.g., at the
800 - 1078 bp region of the CEBPA gene. There are 114
indels in this region and our analysis also showed that
the indel sizes including those in indel hot-spots are far
from random (Fig. 1b). Normally, one- or two-bp indels
and non-3n indels are dominant in both genome and
coding sequences. However, for the 800 - 1078 bp
region of the CEBPA gene, 85% are 3n indels. Com-
pared with the first 800 bp region, the 3n indels are
9.44 times more (85% versus 9%). This great difference
indicates that 3n indels at some loci of indel hot-spots
are also under strong positive selection.
Unfortunately, little is known about such driving
forces. It may vary for different cancer genes, because
the strength of co-occurrence between indels and base
substitutions is different. Notably, all six oncogenes in
Table 1 belong to the ‘apparent’ category that has a
biased mutational pattern. In contrast, the tumor sup-
p r e s s o rg e n e sa r em o r el i k e l yt oh a v eam e d i u mb i a s e d
or more evenly distributed mutational pattern. This fact
suggests that the driving forces, for more 3n bp indels
or more concentrated distribution between indels and
substitutions, may be associated with oncogenesis itself.
This may also shed light on why the strength of co-loca-
lization between indel and substitution is so different
and why the S/I ratio varies considerably among differ-
ent cancer genes. The various pattern and S/I ratio
among the 25 cancer genes in Table 1 may exhibit the
different preference of mutation types in different cancer
genes and the diversified underlying mechanisms of
cancer.
It is also likely that the driving forces are grounded in
a polyclonal epigenetic disruption of stem/progenitor
cells, mediated by ‘tumor-progenitor genes’ [6]. In this
scenario, such genes may trigger a spectrum of muta-
tions, which lead to the selective overgrowth of a
Yang et al. BMC Medical Genetics 2010, 11:128
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Page 9 of 11monoclonal population of tumor cells. To a given gene,
the indel hot-spots may be one of a range of possible
mutations. Although the detailed mechanisms are not
yet clear, indel mutations have apparent important
effects on oncogenes.
Conclusions
All cancers arise from the accumulation of somatic
mutations in cancer related genes. This study analyzed
the mutational patterns of indels and base substitutions
in these genes in the COSMIC database. We found
three distinct patterns of indel distribution in somatic
mutations: high proportion, great abundance and non-
random distribution. A much higher proportion of
indels were observed in somatic mutations, as compared
to meiotic ones. Also, there is a great diversity of indels
at some loci of cancer-related genes. Remarkably in the
genes with abundant mutations, the proportion of 3n
indels in oncogenes is 7.9 times higher than that in
tumor suppressor genes. Considering the dramatic effect
of indels on gene function, the non-random distribution
of indels, particularly the 3n and non-3n indels, may
indicate that indels and their sizes were frequently
under positive selection and can often be the ‘driver
mutations’ in oncogenesis.
Additional material
Additional file 1: This file contains all the supplemental figures and
tables.
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